| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.22 | 0.2 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.061 | 0.2 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |